THC-E (exact composition unknown), topical application four times daily for two weeks
74-year-old man
After repeated surgical interventions, skin grafts and radiotherapy over the last 13 years the malignant lesion completely disappeared within two weeks of daily treatment
64-year-old woman with a history of multiple squamous cell carcinomas
The patient presented with multiple skin lesions on her hands, lichen simplex chronicus on her left and squamous cell carcinoma on her right hand; lesions disappeared within four weeks
Guo TT, Zhang JC, Zhang H, Liu QC, Zhao Y, Hou YF, et al. Bioactive spirans and other constituents from the leaves of Cannabis sativa f. sativa.J Asian Nat Prod Res. 2017;19:793–802. [DOI] [PubMed]
Guo T, Liu Q, Hou P, Li F, Guo S, Song W, et al. Stilbenoids and cannabinoids from the leaves of Cannabis sativa f. sativa with potential reverse cholesterol transport activity.Food Funct. 2018;9:6608–17. [DOI] [PubMed]
Russo C, Lavorgna M, Nugnes R, Orlo E, Isidori M. Comparative assessment of antimicrobial, antiradical and cytotoxic activities of cannabidiol and its propyl analogue cannabidivarin.Sci Rep. 2021;11:22494. [DOI] [PubMed] [PMC]
Tomko AM, Whynot EG, Ellis LD, Dupré DJ. Anti-cancer potential of cannabinoids, terpenes, and flavonoids present in cannabis.Cancers (Basel). 2020;12:1985. [DOI] [PubMed] [PMC]
Li D, Ilnytskyy Y, Gojani EG, Kovalchuk O, Kovalchuk I. Analysis of anti-cancer and anti-inflammatory properties of 25 high-THC cannabis extracts.Molecules. 2022;27:6057. [DOI] [PubMed] [PMC]
Pino S, Espinoza L, Jara-Gutiérrez C, Villena J, Olea AF, Díaz K. Study of cannabis oils obtained from three varieties of C. sativa and by two different extraction methods: phytochemical characterization and biological activities.Plants (Basel). 2023;12:1772. [DOI] [PubMed] [PMC]
Carcieri C, Tomasello C, Simiele M, De Nicolò A, Avataneo V, Canzoneri L, et al. Cannabinoids concentration variability in cannabis oil galenical preparations.J Pharm Pharmacol. 2018;70:143–9. [DOI] [PubMed]
Peeri H, Shalev N, Vinayaka AC, Nizar R, Kazimirsky G, Namdar D, et al. Specific compositions of Cannabis sativa compounds have cytotoxic activity and inhibit motility and colony formation of human glioblastoma cells in vitro.Cancers (Basel). 2021;13:1720. [DOI] [PubMed] [PMC]
Raup-Konsavage WM, Johnson M, Legare CA, Yochum GS, Morgan DJ, Vrana KE. Synthetic cannabinoid activity against colorectal cancer cells.Cannabis Cannabinoid Res. 2018;3:272–81. [DOI] [PubMed] [PMC]
Singh Y, Bali C. Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation.Case Rep Oncol. 2013;6:585–92. [DOI] [PubMed] [PMC]
Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, et al. Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.Psychopharmacology (Berl). 2011;215:505–12. [DOI] [PubMed]
Farrimond JA, Whalley BJ, Williams CM. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.Psychopharmacology (Berl). 2012;223:117–29. [DOI] [PubMed]
Baram L, Peled E, Berman P, Yellin B, Besser E, Benamin M, et al. The heterogeneity and complexity of Cannabis extracts as antitumor agents.Oncotarget. 2019;10:4091–106. [DOI] [PubMed] [PMC]
Raz N, Eyal AM, Zeitouni DB, Hen-Shoval D, Davidson EM, Danieli A, et al. Selected cannabis terpenes synergize with THC to produce increased CB1 receptor activation.Biochem Pharmacol. 2023;212:115548. [DOI] [PubMed]
Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids.J Natl Cancer Inst. 1975;55:597–602. [DOI] [PubMed]
Kander J. Cannabis for the treatment of cancer: the anticancer activity of phytocannabinoids and endocannabinoids. 7th ed. Hill D, Editor. Kindle Edition; 2021.
Guggisberg J, Schumacher M, Gilmore G, Zylla DM. Cannabis as an anticancer agent: a review of clinical data and assessment of case reports.Cannabis Cannabinoid Res. 2022;7:24–33. [DOI] [PubMed] [PMC]
Martell K, Fairchild A, LeGerrier B, Sinha R, Baker S, Liu H, et al. Rates of cannabis use in patients with cancer.Curr Oncol. 2018;25:219–25. [DOI] [PubMed] [PMC]
Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use.Cancer. 2017;123:4488–97. [DOI] [PubMed] [PMC]
Raghunathan NJ, Brens J, Vemuri S, Li QS, Mao JJ, Korenstein D. In the weeds: a retrospective study of patient interest in and experience with cannabis at a cancer center.Support Care Cancer. 2022;30:7491–7. [DOI] [PubMed] [PMC]
Weiss MC, Hibbs JE, Buckley ME, Danese SR, Leitenberger A, Bollmann-Jenkins M, et al. A Coala-T-Cannabis Survey Study of breast cancer patients’ use of cannabis before, during, and after treatment.Cancer. 2021;128:160–8. [DOI] [PubMed] [PMC]
Kenyon J, Liu W, Dalgleish A. Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol.Anticancer Res. 2018;38:5831–5. [DOI] [PubMed]
Blal K, Besser E, Procaccia S, Schwob O, Lerenthal Y, Abu Tair J, et al. The effect of cannabis plant extracts on head and neck squamous cell carcinoma and the quest for Cannabis-based personalized therapy.Cancers (Basel). 2023;15:497. [DOI] [PubMed] [PMC]
Colvin EK, Hudson A, Anderson LL, Kumar RP, McGrego IS, Howell VM, et al. An examination of the anti-cancer properties of plant cannabinoids in preclinical models of mesothelioma.Cancers (Basel). 2022;14:3813. [DOI] [PubMed] [PMC]
Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.J Pharmacol Exp Ther. 2006;318:1375–87. [DOI] [PubMed]
McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.Mol Cancer Ther. 2007;6:2921–7. [DOI] [PubMed]
Sakarin S, Meesiripan N, Sangrajrang S, Suwanpidokkul N, Prayakprom P, Bodhibukkana C, et al. Antitumor effects of cannabinoids in human pancreatic ductal adenocarcinoma cell line (Capan-2)-derived xenograft mouse model.Front Vet Sci. 2022;9:867575. [DOI] [PubMed] [PMC]
Cozzolino R, Cali G, Bifulco M, Laccetti P. Anandamide inhibits human thyroid carcinoma cell lines by activation of apoptosis.Invest New Drugs. 2010;28:115–23.
Singh K, Nassar N, Bachari A, Schanknecht E, Telukutla S, Zomer R, et al. The pathophysiology and the therapeutic potential of cannabinoids in prostate cancer.Cancers (Basel). 2021;13:4107. [DOI] [PubMed] [PMC]
Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos RD, Furtado GP, Moraes MO, Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment.Epigenetics. 2019;14:1164–76. [DOI] [PubMed] [PMC]
Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.Carcinogenesis. 2014;35:2787–97. [DOI] [PubMed]
Raup-Konsavage WM, Carkaci-Salli N, Greenland K, Gearhart R, Vrana KE. Cannabidiol (CBD) oil does not display an entourage effect in reducing cancer cell viability in vitro.Med Cannabis Cannabinoids. 2020;3:95–102. [DOI] [PubMed] [PMC]
Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance.Pharmacol Res. 2021;171:105780. [DOI] [PubMed] [PMC]
Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors.Brain Res. 2007;1137:161–9. [DOI] [PubMed]
Wu X, Han L, Zhang X, Li L, Jiang C, Qiu Y, et al. Alteration of endocannabinoid system in human gliomas.J Neurochem. 2012;120:842–9. [DOI] [PubMed]
Costas-Insua C, Guzman M. Endocannabinoid signaling in glioma.Glia. 2023;71:127–38. [DOI] [PubMed] [PMC]
Calapai F, Cardia L, Sorbara EE, Navarra M, Gangemi S, Calapai G, et al. Cannabinoids, blood–brain barrier, and brain disposition.Pharmaceutics. 2020;12:265. [DOI] [PubMed] [PMC]
Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.Cancer Res. 2004;64:1943–50. [DOI] [PubMed]
Lah TT, Novak M, Pena Almidon MA, Marinelli O, Žvar Baškovič B, Majc B, et al. Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma.Cells. 2021;10:340. [DOI] [PubMed] [PMC]
Nabissi M, Morelli MB, Santoni M, Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents.Carcinogenesis. 2013;34:48–57. [DOI] [PubMed]
Hernán Pérez de la Ossa D, Lorente M, Gil-Alegre ME, Torres S, García-Taboada E, Aberturas Mdel R, et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.PLoS One. 2013;8:e54795. [DOI] [PubMed] [PMC]
Andradas C, Byme J, Kuchibhotla M, Ancliffe M, Jones AC, Carline B, et al. Assessment of cannabidiol and Δ9-tetrahydrocannabinol in mouse models of medulloblastoma and ependymoma.Cancers. 2021;13:330. [DOI] [PubMed] [PMC]
Blázquez C, Salazar M, Carracedo A, Lorente M, Egia A, González-Feria L, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.Cancer Res. 2008;68:1945–52. [DOI] [PubMed]
Fisher Z, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, et al. In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.Curr Oncol. 2016;23:S15–22. [DOI] [PubMed] [PMC]
Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.Nat Med. 2000;6:313–9. [DOI] [PubMed]
Huang T, Xu T, Wang Y, Zhou Y, Yu D, Wang Z, et al. Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.Autophagy. 2021;17:3592–606. [DOI] [PubMed] [PMC]
López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, et al. Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide.Biochem Pharmacol. 2018;157:266–74. [DOI] [PubMed]
Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines.J Pharmacol Exp Ther. 2004;308:838–45.
Messinger D, Harris MK, Cummings JR, Thomas C, Yang T, Sweha SR, et al. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.Neuro Oncol. 2023;25:54–67. [DOI] [PubMed] [PMC]
Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model.Mol Cancer Ther. 2014;13:2955–67. [DOI] [PubMed]
Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.Cell Death Dis. 2015;6:e1601. [DOI] [PubMed] [PMC]
Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.Cancer Res. 2013;73:1559–69. [DOI] [PubMed] [PMC]
Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma.Mol Cancer Ther. 2011;10:90–103. [DOI] [PubMed]
Dall’Stella PB, Docema MFL, Maldaun MVC, Feher O, Lancellotti CLP. Case report: clinical outcome and image response of two patients with secondary high-grade glioma treated with chemoradiation, PCV, and cannabidiol.Front Oncol. 2019;8:643. [DOI] [PubMed] [PMC]
Foroughi M, Hendson G, Sargent MA, Steinbok P. Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas—possible role of Cannabis inhalation.Childs Nerv Syst. 2011;27:671–9. [DOI] [PubMed]
Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, et al. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.Br J Cancer. 2006;95:197–203. [DOI] [PubMed] [PMC]
Likar R, Nahler G. Surprising long term survival in glioblastoma patients treated with cannabidiol.Clin Oncol Res. 2023;6:1–3.
Schloss J, Lacey J, Sinclair J, Steel A, Sughrue M, Sibbritt D, et al. A phase 2 randomised clinical trial assessing the tolerability of two different ratios of medicinal cannabis in patients with high grade gliomas.Front Oncol. 2021;11:649555. [DOI] [PubMed] [PMC]
Twelves C, Sabel M, Checketts D, Miller S, Tayo B, Jove M, et al.; GWCA1208 study group. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.Br J Cancer. 2021;124:1379–87. [DOI] [PubMed] [PMC]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022.CA Cancer J Clin. 2022;72:7–33. [DOI] [PubMed]
Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, García-Taboada E, Villa-Morales M, et al. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.J Natl Cancer Inst. 2015;107:djv077. [DOI] [PubMed]
Song Q, Zhang W, Shi D, Zhang Z, Zhao Q, Wang M, et al. Overexpression of cannabinoid receptor 2 is associated with human breast cancer proliferation, apoptosis, chemosensitivity and prognosis via the PI3K/Akt/mTOR signaling pathway.Cancer Med. 2023;12:13538–50. [DOI] [PubMed] [PMC]
Turcotte C, Blanche MR, Laviolette M, Flamand N. Impact of cannabis, cannabinoids and endocannabinoids in the lungs.Front Pharmacol. 2016;7:317. [DOI] [PubMed] [PMC]
Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidora I, Andradasa C, García-Taboada E, et al. Appraising the “entourage effect”: antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.Biochem Pharmacol. 2018;157:285–93. [DOI] [PubMed]
Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of cannabidiol in breast cancer.Mol Oncol. 2015;9:906–19. [DOI] [PubMed] [PMC]
Fu J, Zhang K, Lu L, Li M, Han M, Guo Y, et al. Improved therapeutic efficacy of CBD with good tolerance in the treatment of breast cancer through nanoencapsulation and in combination with 20(S)-Protopanaxadiol (PPD).Pharmaceutics. 2022;14:1533. [DOI] [PubMed] [PMC]
McKallip RJ, Nagarkatti M, Nagarkatti PS. Δ-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.J Immunol. 2005;174:3281–9. [DOI] [PubMed]
Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.Br J Pharmacol. 2014;171:4464–77. [DOI] [PubMed] [PMC]
Patel N, Kommineni N, Surapaneni SK, Kalvala A, Yaun X, Gebeyehu A, et al. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.Int J Pharm. 2021;607:120943. [DOI] [PubMed] [PMC]
Fraguas-Sánchez AI, Fernández-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Suárez AI. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer.Int J Pharm. 2020;574:118916. [DOI] [PubMed]
Henley AB, Nunn AV, Frost GS, Bell JD. Cannabidiol (CBD) priming enhances cisplatin killing of cancer cells. Proceedings of the 6th European Workshop on Cannabinoid Research; 2013 Apr 18–20; Trinity College Dublin, Ireland. London: British Pharmacological Society; 2013.
Kosgodage US, Mould R, Henley AB, Nunn AV, Guy GW, Thomas EL, et al. Cannabidiol (CBD) is a novel inhibitor for exosome and microvesicle (EMV) release in cancer.Front Pharmacol. 2018;9:889. [DOI] [PubMed] [PMC]
Takeda S, Yamamoto I, Watanabe K. Modulation of Δ9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.Toxicology. 2009;259:25–32. [DOI] [PubMed]
Li LT, Zhao FF, Jia ZM, Qi LQ, Zhang XZ, Zhang L, et al. Cannabinoid receptors promote chronic intermittent hypoxia-induced breast cancer metastasis via IGF-1R/AKT/GSK-3β.Mol Ther Oncolytics. 2021;23:220–30. [DOI] [PubMed] [PMC]
De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.Proc Natl Acad Sci U S A. 1998;95:8375–80. [DOI] [PubMed] [PMC]
Cerretani D, Collodel G, Brizzi A, Fiaschi AI, Menchiari A, Moretti E, et al. Cytotoxic effects of cannabinoids on human HT-29 colorectal adenocarcinoma cells: different mechanisms of THC, CBD, and CB83.Int J Mol Sci. 2020;21:5533. [DOI] [PubMed] [PMC]
Jeong S, Yun HK, Jeong YA, Jo MJ, Kang SH, Kim JL, et al. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells.Cancer Lett. 2019;447:12–23. [DOI] [PubMed]
Chen L, Chen H, Li Y, Li L, Qiu Y, Ren J. Endocannabinoid and ceramide levels are altered in patients with colorectal cancer.Oncol Rep. 2015;34:447–54. [DOI] [PubMed]
Hasenoehrl C, Feuersinger D, Kienzl M, Schicho R. GPR55-mediated effects in colon cancer cell lines.Med Cannabis Cannabinoids. 2019;2:22–8. [DOI] [PubMed] [PMC]
Jung CK, Kang WK, Park JM, Ahn HJ, Kim SW, Taek Oh S, et al. Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer.Oncol Lett. 2012;5:870–6. [DOI] [PubMed] [PMC]
Martínez-Martínez E, Martín-Ruiz A, Martín P, Calvo V, Provencio M, García JM. CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway.Oncotarget. 2016;7:68781–91. [DOI] [PubMed] [PMC]
Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.J Mol Med (Berl). 2012;90:925–34. [DOI] [PubMed]
Romano B, Borrelli F, Pagano E, Cascio MG, Pertwee RG, Izzo AA. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.Phytomedicine. 2014;21:631–9. [DOI] [PubMed]
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network.Br J Cancer. 2011;105:1684–92. [DOI] [PubMed] [PMC]
Simard M, Rakotoarivelo V, Di Marzo V, Flamand N. Expression and functions of the CB2 receptor in human leukocytes.Front Pharmacol. 2022;13:826400. [DOI] [PubMed] [PMC]
Piszcz JA, Pietruczuk M, Kloczko JS, Dabrowska M, Galar M, Milewski MP. Expression of cannabinoid receptors on neoplastic lymphocytes in patients with chronic lymphocytic leukemia.Blood. 2004;104:4804. [DOI]
Kampa-Schittenhelm KM, Salitzky O, Akmut F, Illing B, Kanz L, Salih HR, et al. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation pattern.BMC Cancer. 2016;16:25. [DOI] [PubMed] [PMC]
Melén CM, Merrien M, Wasik A, Sonnevi K, Junlén HR, Christersson B, et al. A clinical trial of cannabis as targeted therapy for indolent leukemic lymphoma.Blood. 2019;134:5487. [DOI]
McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression.Molecular Pharmacol. 2006;70:897–908. [DOI] [PubMed]
McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.Blood. 2002;100:627–34. [DOI] [PubMed]
Huniadi A, Sorian A, Iuhas C, Bodog A, Sandor MI. The effect of cannabis in the treatment of Hodgkin’s lymphoma in a pregnant patient - extensive case report and literature review.J BUON. 2021;26:11–6. [PubMed]
Park SW, Kim JE, Oh SM, Cha WJ, Hah JH, Sung MW. Anticancer effects of anandamide on head and neck squamous cell carcinoma cells via the production of receptor-independent reactive oxygen species.Head Neck. 2015;37:1187–92. [DOI] [PubMed]
Klein Nulent TJ, Van Diest PJ, van der Groep P, Leusink FK, Kruitwagen CL, Koole R, et al. Cannabinoid receptor-2 immunoreactivity is associated with survival in squamous cell carcinoma of the head and neck.Br J Oral Maxillofac Surg. 2013;51:604–9. [DOI] [PubMed]
Liu C, Sadat SH, Ebisumoto K, Sakai A, Panuganti BA, Ren S, et al. Cannabinoids promote progression of HPV-positive head and neck squamous cell carcinoma via p38 MAPK activation.Clin Cancer Res. 2020;26:2693–703. [DOI] [PubMed] [PMC]
Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck.Cancer Epidemiol Biomarkers Prev. 1999;8:1071–8. [PubMed]
Zhang H, Xie M, Levin M, Archibald SD, Jackson BS, Young JE, et al. Survival outcomes of marijuana users in p16 positive oropharynx cancer patients.J Otolaryngol Head Neck Surg. 2019;48:43. [DOI] [PubMed] [PMC]
Kim J, Hua G, Zhang H, Chan TJ, Xie M, Levin M, et al. Rate of second primary head and neck cancer with cannabis use.Cureus. 2020;12:e11483. [DOI] [PubMed] [PMC]
Go YY, Kim SR, Kim DY, Chae SW, Song JJ. Cannabidiol enhances cytotoxicity of anti‑cancer drugs in human head and neck squamous cell carcinoma.Sci Rep. 2020;10:20622. [DOI] [PubMed] [PMC]
Maida V. Medical cannabis in the palliation of malignant wounds—a case report.J Pain Symptom Manage. 2017;53:e4–6. [DOI] [PubMed]
Caputo MP, Rodriguez CS, Padhva TA, Mifsud MJ. Medical cannabis as adjunctive therapy for head and neck cancer patients.Cureus. 2021;13:e18396. [DOI] [PubMed] [PMC]
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma.Hepatology. 2021;73:4–13. [DOI] [PubMed] [PMC]
Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival.J Natl Cancer Inst. 2017;109:djx030. [DOI] [PubMed] [PMC]
Yang J, Tian Y, Zheng R, Li L, Qiu F. Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma.Oncol Lett. 2019;18:1530–8. [DOI] [PubMed] [PMC]
Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma.Cancer Genet Cytogenet. 2006;171:31–8. [DOI] [PubMed]
Shangguan F, Zhou H, Ma N, Wu S, Huang H, Jin G, et al. A novel mechanism of cannabidiol in suppressing hepatocellular carcinoma by inducing GSDME dependent pyroptosis.Front Cell Dev Biol. 2021;9:697832. [DOI] [PubMed] [PMC]
Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.Cell Death Differ. 2011;18:1099–111. [DOI] [PubMed] [PMC]
Sarsembayeva A, Kienzl M, Gruden E, Ristic D, Maitz K, Valadez-Cosmes P, et al. Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells.Front Immunol. 2023;13:997115. [DOI] [PubMed] [PMC]
Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, et al. Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.J Immunol. 2000;165:373–80. [DOI] [PubMed]
Xu S, Ma H, Bo Y, Shao M. The oncogenic role of CB2 in the progression of non-small-cell lung cancer.Biomed Pharmacother. 2019;117:109080. [DOI] [PubMed]
Vidlarova M, Berta E, Prasil P, Prokopova A, Gurska S, Khoylou M, et al. Cannabinoid receptor 2 expression in early-stage non-small cell lung cancers identifies patients with good prognosis and longer survival.Transl Lung Cancer Res. 2022;11:2040–50. [DOI] [PubMed] [PMC]
Hamad H, Olsen BB. Cannabidiol induces cell death in human lung cancer cells and cancer stem cells.Pharmaceuticals (Basel). 2021;14:1169. [DOI] [PubMed] [PMC]
Milian L, Mata M, Alcacer J, Oliver M, Sancho-Tello M, Martín de Llano JJ, et al. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.PLoS One. 2020;15:e0228909. [DOI] [PubMed] [PMC]
Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1.Biochem Pharmacol. 2010;79:955–66. [DOI] [PubMed]
Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1.FASEB J. 2012;26:1535–48. [DOI] [PubMed]
Leelawat S, Leelawat K, Wannakup T, Saingam W, Khamthong N, Madaka F, et al. Anticancer activity of Δ9-tetrahydrocannabinol and cannabinol in vitro and in human lung cancer xenograft.Asian Pac J Trop Biomed. 2022;12:323–32. [DOI]
Ramer R, Rohde A, Merkord J, Rohde H, Hinz B. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.Pharm Res. 2010;27:2162–74. [DOI] [PubMed]
Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, et al. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells.Mol Cancer Ther. 2013;12:69–82. [DOI] [PubMed]
Salles ÉL, Naeini SE, Khodadadi H, Bhandari B, Rezaee S, Threlkeld E, et al. Inhalant cannabidiol impedes tumor growth through decreased tumor stemness and impaired angiogenic switch in NCI-H1437-induced human lung cancer model.Hum Cell. 2023;36:1204–10. [DOI] [PubMed]
Sulé-Suso J, Watson NA, van Pittius DG, Jegannathen A. Striking lung cancer response to self-administration of cannabidiol: a case report and literature review.SAGE Open Medical Case Rep. 2019;7:2050313X19832160. [DOI] [PubMed] [PMC]
Cernovsky ZZ, Litman LC. Case studies of analgesic cannabinoid use by persons with chronic pain from car accidents.Open Sci J Psychol. 2019;6:1–4.
Liew KL, Capuano E, Yung B. Lung cancer patient who had declined conventional cancer treatment: could the self-administration of ‘CBD oil’ be contributing to the observed tumour regression?BMJ Case Rep. 2021;14:e244195. [DOI] [PubMed] [PMC]
Messali EM, Grauso F, Luise R, Angelini A, Rossiello R. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors.Am J Obstet Gynecol. 2014;211:234.e1–6. [DOI] [PubMed]
Barrie AM, Cushue AC, Eskander RN. Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient with metastatic low grade serous ovarian carcinoma.Gynecol Oncol Rep. 2019;29:10–2. [DOI] [PubMed] [PMC]
Fest J, Ruiter R, van Rooij FJ, van der Geest LG, Lemmens VE, Ikram MA, et al. Underestimation of pancreatic cancer in the national cancer registry – reconsidering the incidence and survival rates.Eur J Cancer. 2017;72:186–91. [DOI] [PubMed]
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]
Moreno Roca A, Armijos Acurio L, Jimbo Sotomayor R, Céspedes Rivadeneira C, Rosero Reyes C, López Ayala C. Cohort study of the overall survival of patients with pancreatic cancer in a hospital of specialties of Quito-Ecuador in the period 2007–2017.Innov Surg Sci. 2021;6:75–9. [DOI]
Li Q, Feng Z, Miao R, Liu X, Liu C, Liu Z. Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution.World J Surg Oncol. 2022;20:11. [DOI] [PubMed] [PMC]
Qiu C, Yang L, Wang B, Cui L, Li C, Zhuo Y, et al. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.Biomed Pharmacother. 2019;115:108952. [DOI] [PubMed]
Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, et al. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.Oncogene. 2018;37:6368–82. [DOI] [PubMed]
Carracedo A, Gironella M, Lorente M, Garcia S, Guzmán M, Velasco G, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.Cancer Res. 2006;66:6748–55. [DOI] [PubMed]
Likar R, Nahler G. Cannabidiol possibly improves survival of patients with pancreatic cancer: a case series.Clin Oncol Res. 2020;3:1–4. [DOI]
Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.Cancer. 1997;80:1857–63. [DOI] [PubMed]
Singh R, Meng H, Shen T, Lumahan LEV, Nguyen S, Shen H, et al. TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer.Proc Natl Acad Sci U S A. 2023;120:e2218229120. [DOI] [PubMed] [PMC]
Lopez-Ramos M, Figueroa-Valverde L, Diaz-Cedillo F, Rosas-Nexticapa M, Alvarez-Ramirez M. Theoretical evaluation of twenty-cannabinoid derivatives on either androgen receptor or 5α-reductase enzyme.Clin Cancer Investig J. 2023;12:27–32. [DOI]
Press DJ, Pierce B, Lauderdale DS, Aschebrook-Kilfoy B, Lin Gomez S, Hedeker D, et al. Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago.Prev Med Rep. 2020;20:101174. [DOI] [PubMed] [PMC]
Czifra G, Varga A, Nyeste K, Marincsák R, Tóth BI, Kovács I, et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma.J Cancer Res Clin Oncol. 2009;135:507–14. [DOI] [PubMed]
Sharma M, Hudson JB, Adomat H, Guns E, Cox ME. In vitro anticancer activity of plant-derived cannabidiol on prostate cancer cell lines.Pharmacol Pharma. 2014;5:806–20. [DOI]
De Petrocellis L, Ligresti A, Schiano Moriello A, Iapelli M, Verde R, Stott CG, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.Br J Pharmacol. 2013;168:79–102. [DOI] [PubMed] [PMC]
Motadi LR, Jantjies TE, Moleva B. Cannabidiol and Cannabis sativa as a potential treatment in vitro prostate cancer cells silenced with RBBp6 and PC3 xenograft.Mol Biol Rep. 2023;50:4039–47. [DOI] [PubMed] [PMC]
Myint ZW, St Clair WH, Strup SE, Yan D, Li N, Allison DB, et al. A phase I dose escalation and expansion study of Epidiolex (cannabidiol) in patients with biochemically recurrent prostate cancer.Cancers (Basel). 2023;15:2505. [DOI] [PubMed] [PMC]
Huang J, Huang D, Ruan X, Huang J, Xu D, Heavey S, et al. Association between cannabis use with urological cancers: a population-based cohort study and a mendelian randomization study in the UK biobank.Cancer Med. 2023;12:3468–76. [DOI] [PubMed] [PMC]
Armstrong JL, Hill DS, McKee CS, Hernandez-Tiedra S, Lorente M, Lopez-Valero I, et al. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.J Invest Dermatol. 2015;135:1629–37. [DOI] [PubMed]
Richtig G, Kienzl M, Rittchen S, Roula D, Eberle J, Sarif Z, et al. Cannabinoids reduce melanoma cell viability and do not interfere with commonly used targeted therapy in metastatic melanoma in vivo and in vitro.Biology (Basel). 2023;12:706. [DOI] [PubMed] [PMC]
Adinolfi B, Romanini A, Vanni A, Martinotti E, Chicca A, Fogli S, et al. Anticancer activity of anandamide in human cutaneous melanoma cells.Eur J Pharmacol. 2013;718:154–9. [DOI] [PubMed]
Glodde N, Jakobs M, Bald T, Tüting T, Gaffal E. Differential role of cannabinoids in the pathogenesis of skin cancer.Life Sci. 2015;138:35–40. [DOI] [PubMed]
Simmerman E, Qin X, Yu JC, Baban B. Cannabinoids as a potential new and novel treatment for melanoma: a pilot study in a murine model.J Surg Res. 2019;235:210–5. [DOI] [PubMed]
Grotenhermen F. Canabis bei Krebs: Mehr Chancen als Risiken?Dtsch Zeitschrift für Onkol. 2018;50:188–92. German.
Laborada J, Cohen PR. Cutaneous squamous cell carcinoma and lichen simplex chronicus successfully treated with topical cannabinoid oil: a case report and summary of cannabinoids in dermatology.Cureus. 2022;14:e23850. [DOI] [PubMed] [PMC]
Nahler G. Cannabidiol and other phytocannabinoids as cancer therapeutics.Pharmaceut Med. 2022;36:99–129. [DOI] [PubMed] [PMC]
